SBPA Research LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$285	1
2020	Research	$79,425	26
2019	Research	$119,222	20

Breakdown

Who paid Research payments · program years 2019–2021

United Therapeutics Corporation $176,357 45 payments
Actelion Pharmaceuticals US, Inc. $19,575 1 payment
Janssen Research & Development, LLC $3,000 1 payment

Studies the money was for Research payments · program years 2019–2021

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension PH in Heart Failure With Preserved Ejection Fraction Hfpef $63,925 9 payments
An Open-Label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension PH Associated With Heart Failure With Preserved Ejection Fraction Hfpef - A Long-Term Follow-Up to Study Tde-Hf-301 $25,214 8 payments
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients $23,856 7 payments
Sphere - Ac-065A402 $19,575 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (Hfpef) $18,471 7 payments
An Open-Label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (Hfpef) - A Long-Term Follow-Up to Study Tde-Hf-301 $16,146 6 payments
Adapt - A Patient Registry of the Real-World Use of Orenitram $16,029 7 payments
A Phase 3 Randomized Placebo-Controlled Double-Blind Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Ph?Copd) $12,717 1 payment
Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.